Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
|ClinicalTrials.gov Identifier: NCT01390597|
Recruitment Status : Completed
First Posted : July 11, 2011
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat the cancer.
PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with peripheral T-cell lymphoma or natural killer cell neoplasms.
|Condition or disease||Intervention/treatment|
|Lymphoma||Genetic: DNA analysis Genetic: cytogenetic analysis Genetic: gene mapping Genetic: mutation analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
- To identify mutations in oncogenes and tumor suppressors of peripheral T-cell lymphoma or natural killer (NK) cell neoplasm.
- To delineate the mechanisms that mediate oncogenic effects and their clinical prognostic significance in these diseases.
- To perform a comprehensive mutation analysis via whole exome resequencing in a panel of peripheral T-cell or NK lymphomas.
OUTLINE: Fixed paraffin-embedded tumor tissue samples are analyzed for mutations by the Illumina HiSeq platform. Sequencing reads are performed by GAPipeline version 1.5.1 and mapping on the human genome performed using the MAQ software version 0.7.1. Genes harboring validated somatic mutations are then amplified by PCR and analyzed by Sanger resequencing.
|Study Type :||Observational|
|Actual Enrollment :||32 participants|
|Official Title:||The Molecular Mechanisms of Transformation in Peripheral T-cell and NK Lymphomas|
|Actual Study Start Date :||June 28, 2011|
|Actual Primary Completion Date :||August 28, 2011|
|Actual Study Completion Date :||August 28, 2011|
- New somatically mutated genes in T-cell and NK lymphoma samples [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01390597
|Principal Investigator:||Adolfo A. Ferrando, MD, PhD||Herbert Irving Comprehensive Cancer Center|